Sonnet BioTherapeutics Stock (NASDAQ:SONN)


RevenueOwnershipFinancialsChart

Previous Close

$1.44

52W Range

$1.41 - $18.72

50D Avg

$3.40

200D Avg

$8.56

Market Cap

$4.27M

Avg Vol (3M)

$1.33M

Beta

1.04

Div Yield

-

SONN Company Profile


Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

12

IPO Date

Oct 31, 2006

Website

SONN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 18
Corporate and Other$100.00K
Hooters Full Service$13.84M
Just Fresh Fast Casual$4.05M
Better Burgers Fast Casual$22.62M

Fiscal year ends in Sep 23 | Currency in USD

SONN Financial Summary


Sep 23Sep 22Sep 21
Revenue$147.81K$349.94K$483.63K
Operating Income$-18.79M$-29.67M$-25.09M
Net Income$-18.83M$-29.77M$-25.01M
EBITDA$-18.72M$-29.58M$-24.99M
Basic EPS$-18.14$-150.79$-313.76
Diluted EPS$-18.14$-150.79$-313.76

Fiscal year ends in Sep 23 | Currency in USD

Peer Comparison


TickerCompany
ZVSAZyVersa Therapeutics, Inc.
CNSPCNS Pharmaceuticals, Inc.
IMMXImmix Biopharma, Inc.
ALLRAllarity Therapeutics, Inc.